Across TCGA pan-cancer cohorts, TCF23 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TCF23 data layer compared with 20 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher TCF23 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TCF23 expression acts as an unfavorable survival marker.
COAD and PRAD are the cancer types where TCF23 Mutation most reproducibly stratifies survival.